Download PDF
Drug Res (Stuttg)
DOI: 10.1055/a-2576-4153
Original Article

Protective Effects of Niclosamide Ethanolamine Against Testosterone-Induced Benign Prostatic Hyperplasia in Rats

Ali Hussein Jasim
1   Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq
,
Ahmed Rahmah Abu-Raghif
1   Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq
,
Zeena Ayad Hussein 
1   Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Benign prostatic hyperplasia is a common urological condition in aging men. The anthelmintic agent niclosamide ethanolamide exhibits a wide range of pharmacological activities. This study aimed to evaluate the protective effect of niclosamide ethanolamide in testosterone propionate-induced benign prostatic hyperplasia in rats along with elucidating the probable mechanism of action by investigating the influence on PPAR-γ and Wnt/β-catenin. 40 male Wistar rats were divided randomly into 4 groups. The healthy (control) group, received daily oral and subcutaneous administration of the vehicle. The Induced (TP) group, received only a daily dose of testosterone propionate 3 mg/kg, SC for 28 days. The treated groups (TP+FIN) and (TP+NE), received a concomitant administration of a daily dose of testosterone propionate along with finasteride 5 mg/kg/day and niclosamide ethanolamide 50 mg/kg/day respectively through oral gavage. Animals were euthanized on day 30 of the experiment and prostate tissue samples were collected to evaluate prostate index, prostate hyperplastic markers by ELISA, and gene expression by RT-qPCR. Results revealed that niclosamide ethanolamide significantly reduced prostate index compared to the induced (TP) group (P<0.0001). The agent nearly normalized BPH markers including 5α-reductase type-2 enzyme, dihydrotestosterone, and PCNA compared to the induced (TP) group (P<0.0001). The agent reduced the tissue level of β-catenin while elevating PPAR-γ to control levels (P<0.05). The current study revealed that NE can help prevent BPH in rats by upregulating the PPAR-γ receptor and inhibiting the Wnt pathway.

Keywords

Benign prostatic hyperplasia - Testosterone propionate - PPAR-gamma - Niclisamide ethanolamide - Beta-catenin - 5α-reductase


Publication History

Received: 16 February 2025

Accepted: 31 March 2025

Article published online:
28 April 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Lee SM, Lee SM, Song J. Effects of Taraxaci Herba (Dandelion) on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. Nutrients 2024; 16: 1189
    CrossrefPubMedSearch in Google Scholar
  • 2 Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019; 65: 458-464
    PubMedSearch in Google Scholar
  • 3 Jin BR, Kim HJ, Park SK. et al. Anti-proliferative effects of HBX-5 on progression of benign prostatic hyperplasia. Molecules. 2018; 23: 2638
    PubMedSearch in Google Scholar
  • 4 Elbaz EM, Amin HAA, Kamel AS. et al. Immunomodulatory effect of diallyl sulfide on experimentally-induced benign prostate hyperplasia via the suppression of CD4+T/IL-17 and TGF-β1/ERK pathways. Inflammopharmacol 2020; 28: 1407-1420
    CrossrefPubMedSearch in Google Scholar
  • 5 Lepor H, Kazzazi A, Djavan B. α-Blockers for benign prostatic hyperplasia: the new era. Current opinion in urology 2012; 22: 7-15
    PubMedSearch in Google Scholar
  • 6 Zhang B, Chen X, Gan Y. et al. Dihydroartemisinin attenuates benign prostatic hyperplasia in rats by inhibiting prostatic epithelial cell proliferation. Annals of Translational Medicine. 2021 9.
    PubMedSearch in Google Scholar
  • 7 Shanmugasundaram D, Dwan C, Wimmer BC. et al. Fucoidan Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Rats. Research and Reports in Urology. 2024: 283-297
    PubMedSearch in Google Scholar
  • 8 Olokpa E, Moss PE, Stewart LV. Crosstalk between the androgen receptor and PPAR gamma signaling pathways in the prostate. PPAR research 2017; 2017: 9456020
    PubMedSearch in Google Scholar
  • 9 Kumar R, Coronel L, Somalanka B. et al. Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nature communications 2018; 9: 3931
    PubMedSearch in Google Scholar
  • 10 Jiang H, Li AM, Ye J. The magic bullet: Niclosamide. Frontiers in Oncology 2022; 12: 1004978
    PubMedSearch in Google Scholar
  • 11 Andrews P, Thyssen J, Lorke D. The biology and toxicology of molluscicides, Bayluscide. Pharmacology & therapeutics 1982; 19: 245-295
    PubMedSearch in Google Scholar
  • 12 Alasadi A, Chen M, Swapna GV. et al. Effect of mitochondrial uncouplers niclosamide ethanolamine (NEN) and oxyclozanide on hepatic metastasis of colon cancer. Cell death & disease 2018; 9: 215
    PubMedSearch in Google Scholar
  • 13 Elbaz EM, Alshaymaa D, Amany MG. et al. &quot;Canagliflozin Alleviates Experimentally Induced Benign Prostate Hyperplasia in a Rat Model: Exploring Potential Mechanisms Involving Mir-128b/EGFR/EGF and JAK2/STAT3 Signaling Pathways through in Silico and in Vivo Investigations.&quot;. European Journal of Pharmacology 957 2023; 175993
    CrossrefPubMedSearch in Google Scholar
  • 14 Ali AG, Gorial F, Mahmood A. The anti-rheumatoid activity of niclosamide in collagen-induced arthritis in rats. Archives of Rheumatology 2019; 34: 426
    PubMedSearch in Google Scholar
  • 15 Li J, Tian Y, Guo S. et al. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms. PloS one 2018; 13: e0191469
    PubMedSearch in Google Scholar
  • 16 Underwood W, Anthony R. AVMA guidelines for the euthanasia of animals: 2020 edition. Retrieved on March. 2020 Mar 2013: 2020-2021
    PubMedSearch in Google Scholar
  • 17 Ahmed HA, Gatea FK, Hussein ZA. Azilsartan as a preventive agent against cyclophosphamide-induced testicular injury in male rats. Naunyn-Schmiedeberg&apos;s Archives of Pharmacology. 2024: 1-2
    PubMedSearch in Google Scholar
  • 18 Choi D, Kim J, An J. et al. Amelioration of benign prostatic hyperplasia by costunolide and dehydrocostus lactone in wistar rats. The World Journal of Men&apos;s Health 2019; 39: 315
    PubMedSearch in Google Scholar
  • 19 Abd-Alhussen JK, Al-Kurdy MJ, Hussein SA. In vivo assessment of the anti-benign prostatic hyperplasia effect of hot ethanolic extract of flax seeds in male rats. Open Veterinary Journal 2024; 14: 1928
    PubMedSearch in Google Scholar
  • 20 Khorsheed SM, Abu-Raghif AR, Ridha-Salman H. Alleviative effects of combined topical melatonin and rutin on imiquimod-induced psoriasis mouse model. Pharmacia 2024; 71: 1-13
    CrossrefPubMedSearch in Google Scholar
  • 21 Mahdi ZA, Gatea FK, Hassan OM. et al. The mitigating effect of a topical preparation of amlodipine on imiquimod-induced psoriasis-like lesion in mice. Research Results in Pharmacology 2024; 10: 143-153
    PubMedSearch in Google Scholar
  • 22 Hassan Z, Hassan T, Abu-Raghif A. Evaluation the Effectiveness of Phenolic Compound of Salvia Frigida on Induced Atopic Dermatitis in Experimental Mice. Iraqi Journal of Pharmaceutical Sciences 2022; 31: 154-166
    PubMedSearch in Google Scholar
  • 23 Hussein ZA, Abu-Raghif AR, Fawzi HA. The mitigating effect of para‐hydroxycinnamic acid in bleomycin-induced pulmonary fibrosis in mice through targeting oxidative, inflammatory and fibrotic pathways. Basic & Clinical Pharmacology & Toxicology. 2024
    PubMedSearch in Google Scholar
  • 24 Faul F, Erdfelder E, Lang AG. et al. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior research methods 2007; 39: 175-191
    CrossrefPubMedSearch in Google Scholar
  • 25 Charan J, Kantharia N. How to calculate sample size in animal studies?. Journal of Pharmacology and Pharmacotherapeutics 2013; 4: 303-306
    PubMedSearch in Google Scholar
  • 26 Cha JY, Wee J, Jung J. et al. Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia. Proceedings of the National Academy of Sciences 2015; 112: 9722-9727
    PubMedSearch in Google Scholar
  • 27 Srinivasan M, Jewell SD. Quantitative estimation of PCNA, c-myc, EGFR and TGF-α in oral submucous fibrosis—An immunohistochemical study. Oral oncology 2001; 37: 461-467
    PubMedSearch in Google Scholar
  • 28 Konkol Y, Vuorikoski H, Streng T. et al. Characterization a model of prostatic diseases and obstructive voiding induced by sex hormone imbalance in the Wistar and Noble rats. Transl Androl Urol 2019; 8: S45-S57
    CrossrefPubMedSearch in Google Scholar
  • 29 Campolina-Silva GH, Werneck-Gomes H, Maria BT. et al. Targeting Wistar rat as a model for studying benign, premalignant and malignant lesions of the prostate. Life Sci 242: 117149 2020;
    CrossrefPubMedSearch in Google Scholar
  • 30 Tusubira D, Munezero J, Agu PC. et al. “In-vivo and In-silico Studies Revealed the Molecular Mechanisms of Colocasia Esculenta Phenolics as Novel Chemotherapy against Benign Prostatic Hyperplasia via Inhibition of 5α-reductase and α1-adrenoceptor.”. In Silico Pharmacology 2023; 11: 4
    CrossrefPubMedSearch in Google Scholar
  • 31 Wang Z, Hu L, Salari K. et al. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2. The Journal of pathology 2017; 243: 457-467
    PubMedSearch in Google Scholar
  • 32 Jang YJ, Jung HY, Myeong JY. et al. Effects of alginate oligosaccharide on testosterone-induced benign prostatic hyperplasia in orchiectomized rats. Nutrients. 2023; 15: 682
    PubMedSearch in Google Scholar
  • 33 Chislett B, Chen D, Perera ML. et al. 5-alpha reductase inhibitors use in prostatic disease and beyond. Translational Andrology and Urology 2023; 12: 487
    PubMedSearch in Google Scholar
  • 34 Cappello F, Bucchieri F, Zummo G. 8 Role of immunohistochemical expression of PCNA and p53 in prostate carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas 2002 Jan 1 (Vol. 2, pp. 359-368). Academic Press;
  • 35 Vickman RE, Franco OE, Moline DC. et al. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian journal of urology 2020; 7: 191-202
    PubMedSearch in Google Scholar
  • 36 Bauman TM, Vezina CM, Huang W. et al. Beta-catenin is elevated in human benign prostatic hyperplasia specimens compared to histologically normal prostate tissue. American journal of clinical and experimental urology 2014; 2: 313
    PubMedSearch in Google Scholar
  • 37 Khurana N, Sikka SC. Interplay between SOX9, Wnt/β-catenin and androgen receptor signaling in castration-resistant prostate cancer. International journal of molecular sciences 2019; 20: 2066
    PubMedSearch in Google Scholar
  • 38 Omar HA, Tolba MF. Caffeic acid phenethyl ester guards against benign prostate hypertrophy in rats: Role of IGF-1R/protein kinase-B (Akt)/β-catenin signaling. IUBMB life 2018; 70: 519-528
    PubMedSearch in Google Scholar
  • 39 Wang Z, Yang S, Li Y. et al. Simvastatin improves benign prostatic hyperplasia: role of peroxisome-proliferator-activated receptor-γ and classic WNT/β-catenin pathway. International Journal of Molecular Sciences 2023; 24: 4911
    PubMedSearch in Google Scholar
  • 40 Zhang M, Luo C, Cui K. et al. Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model. World journal of urology 2020; 38: 2933-2943
    PubMedSearch in Google Scholar
  • 41 Froment P, Gizard F, Defever D. et al. Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. Journal of Endocrinology 2006; 189: 199-209
    PubMedSearch in Google Scholar
  • 42 Sato H, Sugai H, Kurosaki H. et al. The effect of sex hormones on peroxisome proliferator-activated receptor gamma expression and activity in mature adipocytes. Biological and Pharmaceutical Bulletin 2013; 36: 564-573
    PubMedSearch in Google Scholar
  • 43 Choi YJ, Kim EK, Fan M. et al. Effect of Paecilomyces tenuipes extract on testosterone-induced benign prostatic hyperplasia in Sprague–Dawley rats. International Journal of Environmental Research and Public Health 2019; 16: 3764
    PubMedSearch in Google Scholar
  • 44 Abo-El Fetoh ME, Abdel-Fattah MM, Mohamed WR. et al. Cyclooxygenase-2 activates EGFR–ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia. Inflammopharmacology. 2023; 31: 499-516
    PubMedSearch in Google Scholar
  • 45 Canda AE, Mungan MU, Yilmaz O. et al. Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. International urology and nephrology 2006; 38: 275-280
    PubMedSearch in Google Scholar
  • 46 Giatti S, Cioffi L, Diviccaro S. et al. Analysis of the finasteride treatment and its withdrawal in the rat hypothalamus and hippocampus at whole-transcriptome level. Journal of Endocrinological Investigation. 2024: 1
    PubMedSearch in Google Scholar
  • 47 Traish AM. Health risks associated with long-term finasteride and dutasteride use: it&apos;s time to sound the alarm. The World Journal of Men&apos;s Health 2020; 38: 323
    PubMedSearch in Google Scholar
  • 48 Tong Y, Zhou RY. Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. Mediators of Inflammation 2020; 2020: 7958316
    PubMedSearch in Google Scholar
  • 49 Schweizer MT, Haugk K, McKiernan JS. et al. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PloS one 2018; 13: e0198389
    PubMedSearch in Google Scholar
  • 50 Katleba KD, Tsamouri MM, Jathal M. et al. Androgen receptor-dependent regulation of metabolism in high grade bladder cancer cells. Scientific reports 2023; 13: 1762
    PubMedSearch in Google Scholar
  • 51 Biersack B. The Antifungal Potential of Niclosamide and Structurally Related Salicylanilides. International Journal of Molecular Sciences 2024; 25: 5977
    PubMedSearch in Google Scholar
  • 52 Kang B, Mottamal M, Zhong Q. et al. Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer. Pharmaceuticals. 2023; 16: 735
    PubMedSearch in Google Scholar
  • 53 Yu X, Liu F, Zeng L. et al. Niclosamide exhibits potent anticancer activity and synergizes with sorafenib in human renal cell cancer cells. Cellular Physiology and Biochemistry 2018; 47: 957-971
    PubMedSearch in Google Scholar
  • 54 Omran MM, Kamal MM, Ammar YA. et al. Pharmacological investigation of new niclosamide-based isatin hybrids as antiproliferative, antioxidant, and apoptosis inducers. Scientific Reports 2024; 14: 19818
    PubMedSearch in Google Scholar
  • 55 Guo Y, Zhu H, Xiao Y. et al. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression. Cell Death & Disease 2022; 13 p 112
    PubMedSearch in Google Scholar
  • 56 Manna MJ, Abu-Raghif A, Muhsin HY. The effect of Niclosamide in acetic acid induce colitis: an experimental study. Prensa méd. argent.. 2019: 309-316
    PubMedSearch in Google Scholar
  • 57 Hernandez-Quiles M, Broekema MF, Kalkhoven E. PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action. Frontiers in endocrinology 2021; 12: 624112
    PubMedSearch in Google Scholar
  • 58 Sharma V, Patial V. Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases. Frontiers in Pharmacology 2022; 13: 991059
    PubMedSearch in Google Scholar
  • 59 Faheem SA, Hazem RM, Elsayed NM. et al. Niclosamide modulates cyclosporin A-induced hepatotoxicity in a mouse model: PPAR-γ and Wnt/β-catenin crosstalk. International Immunopharmacology 2023; 117: 109941
    PubMedSearch in Google Scholar
  • 60 Percie du Sert N, Hurst V, Ahluwalia A. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Journal of Cerebral Blood Flow & Metabolism 2020; 40: 1769-1777
    PubMedSearch in Google Scholar